Related by context. All words. (Click for frequent words.) 73 Bioavailability 73 pharmacodynamic endpoints 71 pharmacodynamic markers 71 Cardiotoxicity 71 Tumor Response 71 metabolite concentrations 71 plasma pharmacokinetics 71 pharmacokinetic parameters 70 hematological parameters 70 pharmacodynamic PD 70 Immunomodulatory 70 Tasigna prolongs 70 dose proportionality 70 clevidipine 70 pharmacodynamic effects 69 haematologic 69 See CLINICAL PHARMACOLOGY 69 electrophysiologic 69 serum biomarkers 69 antiangiogenic agents 69 AST ALT 69 NPM1 mutation 69 exploratory endpoints 69 busulfan 69 galiximab 69 cMET 68 differential gene expression 68 MGd 68 biostatistical analysis 68 Tß4 68 Pharmacokinetic 68 Granulocyte Colony Stimulating Factor 68 fusion enhancers 68 genotypic resistance 68 BEXXAR Therapeutic Regimen 68 pharmacokinetic interactions 68 Fondaparinux 68 Cytotoxic 68 viral kinetics 68 bronchoalveolar lavage 68 hemostatic efficacy 68 pharmacokinetics pharmacodynamics 68 riociguat 68 metabolic parameters 68 Pegylated 68 inflammatory biomarkers 68 antiepileptics 68 pharmacodynamic properties 68 Estrogen Receptor 68 pleiotropic effects 68 preclinical efficacy 68 MAGE A3 ASCI 68 fosbretabulin 68 Danazol 68 Hypercholesterolemia 68 GAMMAGARD 68 Pharmacodynamic 68 hematologic parameters 68 NMDA antagonists 67 prostanoid 67 Meta analyzes 67 plasma lipid 67 urocortin 2 67 serum lipid 67 QTc prolongation 67 ADME properties 67 eTag assays 67 HER2 expression 67 β blockers 67 nicardipine 67 pharmacokinetic characteristics 67 immunomodulation 67 Pharmacokinetic parameters 67 Antiangiogenic 67 tissue oxygenation 67 Deforolimus 67 immuno modulatory 67 CYT# potent vascular disrupting 67 pyridostigmine 67 epoetin alpha 67 elastase 67 p# biomarkers 67 pharmacokinetic PK profile 67 Panzem R NCD 67 vivo potency 67 adrenal suppression 67 immunological responses 67 erythropoietic 67 Clinical Outcome 67 glycosylated hemoglobin HbA1c 67 cytotoxicity assays 67 Aurora Kinase 67 Squalamine 67 hepatotoxic 67 Myocardial Perfusion Imaging 67 p# activation 67 EGFR HER2 67 CYP#A# inhibitors 67 zoledronate 66 relapsed MM 66 immune modulating 66 cardiac repolarization 66 TPMT 66 hMG 66 lipid parameters 66 hepatic insufficiency 66 enzyme immunoassay EIA 66 Hematologic 66 Primary endpoints 66 tumor necrosis 66 neuroleptic 66 Pharmacodynamics 66 Cystatin C 66 antitumor efficacy 66 Afatinib 66 Interferon Beta 66 INVEGA ® 66 NMDA antagonist 66 inhaled iloprost 66 selective modulator 66 Hepatotoxicity 66 Immunotherapeutic 66 paroxetine sertraline 66 pharmacodynamic profiles 66 mechanistic insights 66 favorable pharmacokinetic profile 66 metastatic neuroendocrine tumors 66 hERG 66 Triapine R 66 pathophysiological effects 66 CINQUIL 66 platelet dysfunction 66 uricase 66 myopathy rhabdomyolysis 66 cannabinor 66 baseline LDH 66 CINTREDEKIN BESUDOTOX 66 immune modulatory 66 EDEMA3 trial 66 neuropsychiatric diseases 66 dosimetric 66 serum phosphate 66 R Saizen R 66 Cardiorespiratory fitness 66 echocardiographic parameters 66 liposome formulation 66 tumor histology 66 Non inferiority 66 thalidomide Thalomid 66 physico chemical properties 66 endothelin antagonists 66 meta regression 66 Teriflunomide 66 Prostacyclin 66 tolerability pharmacokinetics 66 antiangiogenic therapy 66 torsemide ER 66 direct thrombin inhibitors 66 antitumor effect 66 nonclinical studies 66 serum PTH 66 Antitumor 66 Thalomid ® 66 preclinical pharmacokinetic 66 anti androgens 66 Multivariate logistic regression 66 bone metabolism 66 QTc intervals 66 Anticalins ® 66 plasma lipids 66 SPRYCEL ® 66 RQ PCR 66 analgesic efficacy 66 lipid lowering agents 66 pegylated IFN 66 WARNINGS Myopathy Rhabdomyolysis 66 Initiate Clinical Trial 66 Incretin 66 Nebulized 66 GERD migraine headaches 66 paricalcitol 66 Fibrates 66 biodistribution studies 65 pharmacodynamics PD 65 Fulvestrant 65 serum leptin 65 anticholinergic agents 65 tumorigenicity 65 biodistribution 65 dosage regimens 65 5 Fluorouracil 65 STRIDE PD 65 therapeutic regimens 65 opioid mediated 65 MGN# 65 ß blockers 65 telomerase inhibition 65 cytopenias 65 lipid lowering therapies 65 linear pharmacokinetics 65 HPA axis suppression 65 aminotransferases 65 epigenetic therapies 65 alemtuzumab MS 65 VP# [004] 65 somatostatin analogues 65 antiangiogenic activity 65 antiplatelet medications 65 bezafibrate 65 Creatinine 65 oral prodrug 65 lactate dehydrogenase LDH 65 ORENCIA R 65 mechanistic studies 65 poly ethylene glycol PEG 65 Anticholinergic 65 Anti Tumor 65 MYCAMINE 65 Demonstrates Efficacy 65 Long Term Efficacy 65 prasterone 65 peripheral insulin sensitivity 65 neurocognitive function 65 antidiabetic medications 65 CIMZIA ™ 65 vitro cytotoxicity 65 Inhalation Solution 65 antineoplastic 65 demonstrated clinically meaningful 65 CIMZIA TM certolizumab pegol 65 Solorel TM 65 acamprosate calcium 65 topically administered 65 Pharmacokinetic PK 65 ritonavir boosted 65 cediranib 65 Neurogenesis 65 demonstrated antitumor activity 65 aminotransferase 65 Paliperidone ER 65 myeloproliferative diseases 65 pharmacokinetic pharmacodynamic 65 pharmacokinetic equivalence 65 APOE genotype 65 Azedra 65 alfuzosin 65 induced sputum 65 mGluR5 NAM 65 ZOLINZA 65 Nonclinical 65 Patients Receiving 65 sipuleucel T 65 HCV protease inhibitors 65 systemically administered 65 intravascular hemolysis 65 flavopiridol 65 nonsteroidal antiinflammatory drugs 65 flutamide 65 LEP ETU 65 potentially hepatotoxic 65 Toxicities 65 Vildagliptin 65 Glucocorticoids 65 bovine thrombin 65 novel VDA molecule 65 Antitumor Activity 65 antiplatelet therapies 65 Factor Receptor 65 Neuroprotective 65 Demonstrates Positive 65 CIMZIA R 65 Darinaparsin 65 bronchoalveolar lavage fluid 65 Diabetic Foot Ulcer 65 PI3K/mTOR 65 GRNCM1 65 exendin 4 65 Azacitidine 65 hepatic enzyme 65 lipid altering 65 Coronary CTA 65 fibrotic disease 65 myelofibrosis polycythemia vera 65 HGS ETR2 65 teriflunomide 65 pharmacokinetic profiles 65 Kidney Function 65 F FDG PET 65 Warfarin Coumadin 65 K ras mutations 65 histological subtype 65 edifoligide E2F Decoy 65 delafloxacin 65 colesevelam HCl 65 hemodynamic measurements 65 tigecycline 65 microdose 65 Symptom severity 65 Teriparatide 65 #ME# 65 JAK Inhibitor 65 FOSRENOL ® 65 OMS# 65 Shows Statistically Significant 65 serum phosphorous 65 sitaxsentan 65 CYP#A# substrate 65 rHuPH# 65 pharmacological approaches 65 Pivotal Phase III 65 Aeolus Pharmaceuticals Announces 65 prospective multicentre 65 r hGH 65 Vidaza azacitidine 65 IFN α 65 infusional 65 Secretase 65 radiation dosimetry 65 tacrolimus ointment 65 proton MR spectroscopy 65 hypericin 65 Retinoic Acid 65 immunofluorescence microscopy 65 cytokines chemokines 64 lanthanum carbonate 64 angiographic outcomes 64 circadian genes 64 taxane resistant 64 Technosphere ® 64 β carotene 64 antioxidant supplementation 64 erlotinib Tarceva ® 64 p# biomarker 64 Oral Fingolimod 64 physicochemical properties 64 prognostic variables 64 kidney urologic 64 potency selectivity 64 immunomodulatory agents 64 hyperoxaluria 64 Adverse Event 64 Pegylated Interferon 64 coadministration 64 etiologic 64 pharmacokinetic PK 64 TLK# 64 denileukin diftitox 64 intensive lipid lowering 64 trastuzumab Herceptin ® 64 abacavir Ziagen 64 KRAS status 64 NeuroSTAT ® 64 radiolabeled TM# 64 #ß 64 Adverse effects 64 Pafuramidine 64 antiviral efficacy 64 docetaxel Taxotere ® 64 bFGF 64 bronchoalveolar lavage BAL 64 QT interval prolongation 64 pharmacokinetics PK 64 efficacy tolerability 64 lung epithelium 64 CANCIDAS 64 Humate P 64 mTOR inhibitors 64 griseofulvin 64 AGHD 64 serum cortisol 64 Lymphoid 64 physiologic parameters 64 tolerability profiles 64 Pharmacokinetics PK 64 aspartate aminotransferase AST 64 LPM TM 64 Interferon beta 64 anti CD3 64 radiotherapy RT 64 rxRNA 64 mitochondrial toxicity 64 corrected QT interval 64 florbetaben 64 ADVEXIN therapy 64 DNA methylation markers 64 antimetabolites 64 Dehydrogenase 64 antitumour 64 glomerular filtration 64 anticancer activity 64 atherogenic dyslipidemia 64 systemic hypotension 64 urate lowering 64 #beta estradiol 64 isotypes 64 divalproex sodium 64 hepatic fibrosis 64 CYP#C# [002] 64 Poly ICLC 64 Vaxfectin TM 64 AChE inhibitors 64 ENMD # 64 Mg Uk 64 PDX pralatrexate 64 Recombinant Human 64 basal bolus regimen 64 pain palliation 64 Alequel 64 CaPre TM 64 neurodevelopmental outcome 64 topoisomerase II inhibitor 64 unfractionated heparin UFH 64 urodynamic 64 effector function 64 Demonstrated Significant 64 Trofex 64 weekly subcutaneous injections 64 microsomal 64 prucalopride 64 Bisphosphonate 64 induce orthostatic hypotension 64 Acute Ischemic Stroke 64 CTAP# Capsules 64 morphometric vertebral fractures 64 Synthetic Peptide 64 Cytochrome P# 64 colorectal adenocarcinoma 64 hemodynamic variables 64 antithrombotics 64 APTIVUS 64 Known hypersensitivity 64 inhibitor RG# 64 IgG1 antibodies 64 ERK signaling 64 BANZEL 64 Daptomycin 64 antiresorptive 64 Transdermal Delivery 64 EOquin TM phase 64 ancrod 64 heparanase 64 coagulation abnormalities 64 C1 Inhibitor 64 Skeletal Muscle 64 Quantitation 64 chemosensitivity 64 Cholinesterase Inhibitors 64 triglyceride concentrations 64 nonhematologic adverse reactions 64 Androgel R 64 concomitant medications 64 serum calcium 64 intradermal injections 64 monoamine oxidase inhibitors 64 Solid Tumors 64 Androxal TM 64 Initiates Clinical Trial 64 PROCRIT R 64 CDK inhibitor 64 vapreotide acetate 64 renal toxicity 64 fulvestrant 64 Cleviprex TM clevidipine 64 posaconazole 64 nalbuphine ER 64 CYP#D# inhibitors 64 p# inhibitor 64 cerebral oxygenation 64 Eculizumab 64 prospectively stratified 64 prognostic indicators 64 tiagabine 64 MP4OX 64 Lp PLA 2 64 eculizumab therapy 64 metabolomic profiling 64 Paliperidone 64 serum antibody 64 Natalizumab 64 tumor subtypes 64 Akt activation 64 hypocalcaemia 64 pharmacodynamic 64 aldosterone antagonist 64 Hypotension 64 ionotropic 64 Gastrointestinal Stromal Tumors 64 fibrin deposition 64 memantine Namenda 64 Enzyme Replacement Therapy 64 platelet inhibition 64 developmental neurotoxicity 64 cytoprotective 64 INVEGA ™ 64 Entereg R 64 azacytidine 64 intact parathyroid hormone 64 osteogenic 64 ergot alkaloids 64 nonpharmacologic 64 torsade de pointes 64 warfarin dosage 64 HIV HCV coinfected 64 Calcitonin 64 Meets Primary Endpoint 64 mecamylamine 64 mutated K ras 63 nutlin 3a 63 vascular reactivity 63 TLR antagonists 63 CYP #A# 63 lucinactant 63 vernakalant hydrochloride 63 pulmonary exacerbations 63 Mimetics 63 abacavir lamivudine 63 OBPM 63 antidepressant efficacy 63 prostaglandin analogues 63 VEGF expression 63 radiographic outcomes 63 urinary N telopeptide 63 fluvastatin 63 serum lipid levels 63 Biocompatibility 63 radiographic findings 63 acetonide FA 63 BENICAR HCT 63 Golimumab 63 Clinical Relevance 63 hepatic enzymes 63 KRAS mutation 63 immunotoxicity 63 Xanafide 63 Pegloticase 63 intestinal mucosal 63 metaplasia 63 Cloretazine 63 QT intervals 63 Fracture Risk 63 salmeterol fluticasone 63 Solazed TM 63 biologic DMARD 63 ULTRAM ER 63 Homeostasis 63 pentoxifylline 63 hematopoietic cancers 63 cisplatin gemcitabine 63 immunostimulatory effects 63 APTIVUS r 63 Helicobacter pylori eradication 63 platelet aggregation inhibitors 63 Growth Hormone Deficiency 63 glycosylated hemoglobin levels 63 immunomodulatory properties 63 beta interferons 63 FUSILEV enhances 63 lenalidomide dexamethasone 63 Bioequivalence 63 Intravenous Immunoglobulin 63 Tasimelteon 63 INSPIRE Trial Phase III 63 5alpha reductase 63 Placebo Controlled Trial 63 Tolvaptan 63 non nucleoside 63 Ischemic 63 Valortim ® 63 Fluticasone 63 neurosensory 63 transgene expression 63 intracranial hemorrhage ICH 63 INTEGRILIN 63 catheter occlusion 63 PBMCs 63 Hematopoietic 63 ImmuKnow 63 Histologic 63 ESBA# 63 Cytarabine 63 gastric adenocarcinoma 63 Diabetic Neuropathy 63 Reproducibility 63 adrenocorticotropic hormone 63 hyperphenylalaninemia HPA due 63 Renal dysfunction 63 biochemical abnormalities 63 mTOR inhibition 63 RISPERDAL ® 63 severe gastroparesis 63 serum calcium levels 63 fumagillin nanoparticles 63 interferon gamma 1b 63 biomolecular interactions 63 unresectable tumors 63 Topiramate 63 vitamin B# folic acid 63 Exacerbations 63 pleural fluid 63 Chemophase 63 LAB CGRP 63 metal cations 63 severe hypersensitivity reactions 63 Methylnaltrexone 63 serum retinol 63 ORENCIA ® 63 poststroke depression 63 doxorubicin HCl 63 Carfilzomib 63 CPAP adherence 63 neratinib 63 PNH patients 63 hyaluronidase enzyme 63 CLA isomers 63 antiarrhythmic 63 topical calcineurin inhibitors 63 HMG CoA reductase inhibitors 63 macrolide antibiotic 63 Echocardiographic 63 Oral Formulation 63 Plasmin 63 Excretion 63 ara C 63 immunostaining 63 certolizumab 63 hematopoietic malignancies 63 bronchial hyperresponsiveness 63 Hepatocytes 63 antiplatelet drugs 63 Antidiabetic 63 Glycosylation 63 gastrointestinal absorption 63 myocardial infarct size 63 thyrotropin 63 prospective multicenter study 63 pharmacokinetic PK study 63 dose proportional pharmacokinetics 63 interleukin IL -# 63 postprandial glycemia 63 factor TNF 63 Prolongs Survival 63 natriuretic peptides 63 allopregnanolone 63 hepatitis B immunoglobulin 63 microtubule inhibitor 63 alpha interferons 63 circulating endothelial cells 63 Antiviral Activity 63 Tr DNA 63 apolipoprotein B 63 Seliciclib 63 Hsp# Inhibitor 63 Cardiopulmonary bypass 63 Refractory Hodgkin Lymphoma 63 SUSTENNA TM 63 Extracellular Matrix 63 endothelial activation 63 LT NS# 63 ALA PDT 63 Onconase 63 NDA Submission 63 aplindore 63 hepatoma 63 antiandrogens 63 Pemetrexed 63 drug eluting stent implantation 63 ICH guidelines 63 empiric therapy 63 nephrotoxicity 63 flecainide 63 molecular biomarkers 63 topical formulations 63 Catheter Associated 63 QT QTc 63 teratogenicity 63 mixed hyperlipidemia 63 Dasatinib 63 mean ± SEM 63 peptidic 63 plasma renin activity 63 platelet activation 63 colorectal liver metastases 63 immunomodulatory therapy 63 hA# 63 Pharmacologic 63 Conjugated 63 TPI ASM8 63 androgen suppression 63 interobserver reliability 63 steroid dexamethasone 63 airway responsiveness 63 cobiprostone 63 ganaxolone 63 Tiotropium 63 NATRECOR ® 63 visilizumab 63 Prospective Randomized 63 Zemplar Capsules 63 Microplasmin 63 Inhibitory 63 PDE# inhibitors 63 uric acid lowering 63 vidofludimus 63 Immune Responses 63 Epidermal Growth Factor Receptor 63 Pyridorin 63 sorafenib tablets 63 itraconazole Sporanox 63 tardive dyskinesia TD 63 Platinol ® 63 non selective NSAIDs 63 velafermin 63 Androgen 63 AT1R 63 treating neuropathic pain 63 dopamine D2 63 Enzastaurin 63 Decitabine 63 ABCB1 63 spirometric 63 synthetic retinoid 63 extracellular dopamine 63 Progenitor Cells 63 lymphocyte proliferation 63 Pioglitazone 63 INTEGRILIN R 63 Metabolic Disorder 63 Signaling Pathways 63 mesalamine granules 63 HER2 overexpression 63 VEGF inhibitors 63 phototoxicity 63 endometrial hyperplasia 63 iloprost 63 injectable formulations 63 anti angiogenic agents 63 cTnI 63 selenium supplementation 63 Corgentin 63 guanfacine extended release 63 Tyrosine Kinase Inhibitor 63 EGFR mutation status 63 interferon alfa 2b 63 oxcarbazepine 63 Angiotensin converting enzyme 63 cholestyramine 63 antifibrotic 63 EXPAREL ™ 63 bortezomib Velcade 63 neurite outgrowth 63 avosentan 63 Anthracycline 63 physiologic responses 63 vasoactive 63 metaanalysis 63 dyslipidaemia 63 DaTscan 63 intermittent dosing 63 antidiabetic drugs 63 pretransplant 63 Thiazolidinediones 63 either acutely decompensated 63 hPTH #-# 63 Iloperidone 63 venous thromboembolic disease 63 gp# vaccine 63 dosing frequency 63 potent cytotoxic 63 Insulin detemir 63 complement inhibitor eculizumab 63 TNFalpha 63 Aspergillus nidulans 63 Perforomist ™ Inhalation Solution 63 bioavailable testosterone 63 NAbs 63 topical NSAIDs 63 vasodilatation 63 oral picoplatin 63 biologic therapeutics 63 synthetic siRNA 63 antimuscarinic 63 reactogenicity 63 perfusion abnormalities 63 SinuNase TM 63 toxicologic 63 clomipramine 63 anti miRs 63 inotropic agents 63 VDAs 63 ISTODAX 63 5 HT1A receptor 63 inhibit platelet function 63 intranasal delivery 63 maximally tolerated dose 63 Schizophrenia Treatment 63 Histopathologic 63 Kinoid 63 enzyme kinetics 63 AERx ® 63 HDL Selective Delipidation 63 prolactin elevation 63 Mg Usa 63 peripheral blood mononuclear 63 Outpatient Setting 63 RE LY ® 63 somatosensory evoked potentials 63 von Willebrand Factor 63 multiple logistic regression 63 HCV SPRINT 63 Malignant Glioma 63 immunomodulatory effects 63 INFERGEN 63 APTIVUS ritonavir 63 thetreatment 63 Sapacitabine 63 GnRH agonists 63 potent suppressor 63 parasitemia 63 papillary renal cell carcinoma 62 Chemotherapeutic Agents 62 IL# PE#QQR 62 BAL# [002] 62 vasodilators 62 mGlu2 3 62 prostaglandin E1 62 EOquin TM 62 calcium antagonists 62 prognostic markers 62 Showed Significant 62 surrogate markers 62 Retreatment 62 aripiprazole Abilify 62 biophysical techniques 62 ACE Inhibitors 62 PEG SN# 62 systemic immunosuppressive drugs 62 Biolimus A9 62 enzymatic pathways 62 gp# protein [002] 62 naltrexone hydrochloride 62 CCX# 62 Phase IIB 62 PXD# 62 aspirin clopidogrel 62 oral antidiabetic medication 62 inotropes 62 Pegylated Liposomal Doxorubicin 62 Clolar ® 62 clinicopathological features 62 Novolimus 62 Naive Patients 62 zonisamide SR 62 liver histology 62 cromolyn sodium 62 MTT assay 62 recurrent glioblastoma multiforme 62 plasma lipoprotein 62 eprotirome 62 secondary hyperparathyroidism 62 Xcytrin R 62 transcranial Doppler ultrasound 62 Small Molecule 62 transaminase levels 62 Bosentan 62 IgG antibody 62 Preclinical Study 62 generation NNRTI 62 HIF PH inhibitors 62 Rigorous scientific 62 efalizumab 62 hemodynamic parameters 62 Tacrolimus 62 2 methoxyestradiol 62 REMINYL ® 62 Protelos R 62 NPH insulin 62 Virologic 62 Relapsing Multiple Sclerosis 62 KRAS mutations 62 Systemic Delivery 62 CYP #D# 62 caspofungin 62 myocardial uptake 62 acitretin 62 Phase 2b Clinical Trial 62 leucocyte 62 LNP formulations 62 PDE inhibitors 62 anti resorptive 62 RNAi Therapeutic 62 favorable pharmacokinetic 62 Orally administered 62 sorafenib Nexavar 62 beta 1a 62 Vaxfectin R 62 RRM1 62 indinavir 62 receptor inhibitor 62 CRLX# 62 peptide conjugated 62 tubulin inhibitor 62 statin monotherapy 62 piroxicam 62 Anticalins R 62 PRADAXA 62 vildagliptin 62 radiochemotherapy 62 serum bicarbonate 62 hypomagnesemia 62 amifostine 62 histopathologic diagnosis 62 Xelox 62 apolipoproteins 62 virological response 62 triiodothyronine 62 neurologic progression 62 receptor subtypes 62 renoprotective 62 triglyceride lowering 62 Antithrombin 62 Diffuse Large B 62 thiazide 62 alkylating agent 62 Safinamide 62 poor metabolizers 62 LOVENOX R 62 pharmacologic treatments 62 oral antidiabetic 62 Inflammatory Pain 62 SILENOR 62 dorzolamide 62 generalized estimating 62 oncologic outcomes 62 Double Blind Randomized 62 intra abdominal abscess 62 Novel Oral 62 labetalol 62 Aliskiren 62 Valsartan 62 sargramostim 62 ON #.Na 62 serum homocysteine 62 Lyophilized 62 XP# XP# 62 Azedra ™ 62 DMARDS 62 crizotinib PF # 62 opioid naive 62 liposomal amphotericin B 62 fibrate drugs 62 Antipsychotic 62 STAT3 signaling 62 glial tumors 62 hyperprolactinemia 62 Platelet Inhibition 62 endothelin receptor antagonists 62 receptor tyrosine kinase inhibitor 62 immunohistochemical analysis 62 nomograms 62 Estradiol 62 mediated inhibition 62 Zevalin consolidation 62 metastatic lymph nodes 62 rhITF 62 Th2 cytokines 62 Benazepril 62 investigational therapies 62 Cytotoxicity 62 isoproterenol 62 pan HDAC inhibitor 62 platelet reactivity 62 preclinical pharmacology 62 neurocognitive outcomes 62 LHRH antagonists 62 DermaVir Patch 62 Univariate 62 betamethasone dipropionate 62 FGFs 62 efaproxiral 62 cis retinoic acid 62 CYP#D# inhibitor 62 Chemokine Receptor 62 histopathological 62 gefitinib Iressa 62 #T# L1 62 Statistically Significant 62 selective cyclooxygenase 2 62 PSMA ADC 62 pioglitazone HCl 62 sonographic diagnosis 62 Demonstrate Significant 62 calcineurin inhibitors 62 Mycophenolate Mofetil 62 cytostatic 62 Secondary Hyperparathyroidism 62 Electrophysiological 62 immunosuppressive agents 62 Scale PANSS 62 QT Prolongation